Cargando…

Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials

INTRODUCTION: We report on a meta-analysis of Silexan, a proprietary active substance produced from Lavandula angustifolia, in subthreshold anxiety, mixed anxiety and depressive disorder (MADD), and generalized anxiety disorder (GAD). METHODS: The present analyses are based on all currently complete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dold, Markus, Bartova, Lucie, Volz, Hans-Peter, Seifritz, Erich, Möller, Hans-Jürgen, Schläfke, Sandra, Kasper, Siegfried
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465640/ https://www.ncbi.nlm.nih.gov/pubmed/36717399 http://dx.doi.org/10.1007/s00406-022-01547-w

Ejemplares similares

Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited
por: Bartova, Lucie, et al.
Publicado: (2022)

Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials
por: Möller, Hans-Jürgen, et al.
Publicado: (2017)

No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial
por: Seifritz, Erich, et al.
Publicado: (2020)

Silexan for treatment of anxiety and depression in the context of COVID-19
por: Bartova, Lucie, et al.
Publicado: (2023)

Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta‐analysis
por: von Känel, Roland, et al.
Publicado: (2021)

Silexan for treatment of psychiatric manifestations in the context of COVID-19: a case series
por: Bartova, L., et al.
Publicado: (2023)

The relevance of ‘mixed anxiety and depression’ as a diagnostic category in clinical practice
por: Möller, Hans-Jürgen, et al.
Publicado: (2016)

No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel Combination
por: Heger-Mahn, Doris, et al.
Publicado: (2014)

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

Efficacy and safety of lavender essential oil (Silexan) capsules among patients suffering from anxiety disorders: A network meta-analysis
por: Yap, Wuan Shuen, et al.
Publicado: (2019)

Combining machine learning algorithms for prediction of antidepressant treatment response
por: Kautzky, Alexander, et al.
Publicado: (2020)

Effects of Silexan on the Serotonin-1A Receptor and Microstructure of the Human Brain: A Randomized, Placebo-Controlled, Double-Blind, Cross-Over Study with Molecular and Structural Neuroimaging
por: Baldinger, Pia, et al.
Publicado: (2015)

Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials
por: Dold, Markus, et al.
Publicado: (2015)

PS75. Psychopharmacoepidemiology of Major Depressive Disorder in European Tertiary Psychiatric Treatment Centers
por: Bartova, Lucie, et al.
Publicado: (2016)

Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression
por: Fugger, Gernot, et al.
Publicado: (2020)

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder
por: Bartova, Lucie, et al.
Publicado: (2021)

The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
por: Fugger, Gernot, et al.
Publicado: (2022)

Age as a moderating factor of treatment resistance in depression
por: Kautzky, Alexander, et al.
Publicado: (2023)

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder
por: Dold, M., et al.
Publicado: (2018)

Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression
por: Bartova, Lucie, et al.
Publicado: (2021)

Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)
por: Dold, Markus, et al.
Publicado: (2018)

Implementing prevention of seasonal affective disorder from patients’ and physicians’ perspectives – a qualitative study
por: Nussbaumer-Streit, Barbara, et al.
Publicado: (2018)

Psychotherapy employed additionally to Psychopharmacotherapy is not related to Better Treatment Outcome in Major Depressive Disorder
por: Bartova, L., et al.
Publicado: (2022)

PS226. The efficacy of light therapy in the treatment of seasonal affective disorder: A meta-analysis of randomized controlled trials
por: Friedrich, M-E., et al.
Publicado: (2016)

Case Report: Bupropion Reduces the [(123)I]FP-CIT Binding to Striatal Dopamine Transporter
por: Milenkovic, Ivan, et al.
Publicado: (2021)

Torgny Svensson, a superb mind and an inspiring colleague
por: Kasper, Siegfried, et al.
Publicado: (2020)

Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication?
por: Seemüller, Florian, et al.
Publicado: (2012)

The fear of being laughed at as additional diagnostic criterion in social anxiety disorder and avoidant personality disorder?
por: Havranek, Michael M., et al.
Publicado: (2017)

Prescription of Silexan Is Associated with Less Frequent General Practitioner Repeat Consultations Due to Disturbed Sleep Compared to Benzodiazepine Receptor Agonists: A Retrospective Database Analysis
por: Krüger, Tillmann, et al.
Publicado: (2022)

The media and intellectuals' response to medical publications: the antidepressants' case
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2013)

Inflammatory processes and schizophrenia: two independent lines of evidence from a study of twins discordant and concordant for schizophrenic disorders
por: Braun, Silke, et al.
Publicado: (2017)

Investigating Relationships Among Self-Efficacy, Mood, and Anxiety Using Digital Technologies: Randomized Controlled Trial
por: Rohde, Judith, et al.
Publicado: (2023)

PM478. Imaging the effects of d-amphetamine in the human brain for modelling dopaminergic alterations in schizophrenia
por: Willeit, Matthäus, et al.
Publicado: (2016)

Superior efficacy of St John's wort extract WS(® )5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]
por: Kasper, Siegfried, et al.
Publicado: (2006)

Editorial: Bridging the gap: an interdisciplinary perspective on ketamine in psychiatric disorders
por: Hartelius, Glenn, et al.
Publicado: (2023)

Making Sense of: Sensitization in Schizophrenia
por: Weidenauer, Ana, et al.
Publicado: (2016)

Successfully treating acutely ill patients: does it improve long-term outcome in psychiatric disorders?
por: Hans-PeterVolz
Publicado: (2007)

The EPA/EADS/ESC position statement on diabetes and cardiovascular risk in patients with severe mental disorders
por: Möller, Hans-Jurgen
Publicado: (2010)

Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study
por: Meyer, Bernhard M., et al.
Publicado: (2019)

The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 4: Unmet Needs in the Treatment of Bipolar Disorder and Recommendations for Future Research
por: Fountoulakis, Konstantinos N., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bdgrhannum473esh6hlq2901hr